# Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement

> **NCT05053308** · NA · WITHDRAWN · sponsor: **Seoul National University**

## Conditions studied

- Cancer Pain
- Breakthrough Pain

## Interventions

- **DRUG:** Intravenous Infusion
- **DRUG:** Sublingual Tablet

## Key facts

- **NCT ID:** NCT05053308
- **Lead sponsor:** Seoul National University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-12-01
- **Primary completion:** 2023-05-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The supply of IP is disrupted
- **Last updated:** 2023-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05053308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05053308, "Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05053308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*